CL2011001757A1 - Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico. - Google Patents

Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico.

Info

Publication number
CL2011001757A1
CL2011001757A1 CL2011001757A CL2011001757A CL2011001757A1 CL 2011001757 A1 CL2011001757 A1 CL 2011001757A1 CL 2011001757 A CL2011001757 A CL 2011001757A CL 2011001757 A CL2011001757 A CL 2011001757A CL 2011001757 A1 CL2011001757 A1 CL 2011001757A1
Authority
CL
Chile
Prior art keywords
glucopyranos
pharmaceutical composition
sglt2
yloxy
tetrahydrofuran
Prior art date
Application number
CL2011001757A
Other languages
English (en)
Inventor
Leo Thomas
Michael Mark
Peter Eickelmann
Leo John Seman
Uli Broedl
Rolf Grempler
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001757(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2011001757A1 publication Critical patent/CL2011001757A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Método para prevenir, frenar el avance, retrasar o tratar un trastorno metabólico tal como diabetes mellitus porque comprende el uso de un compuesto derivado de beta-d-glucopiranos; composición farmacéutica y su uso.
CL2011001757A 2009-02-13 2011-07-20 Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico. CL2011001757A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15231809P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
CL2011001757A1 true CL2011001757A1 (es) 2011-10-28

Family

ID=42008536

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001757A CL2011001757A1 (es) 2009-02-13 2011-07-20 Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico.

Country Status (28)

Country Link
US (8) US20110046087A1 (es)
EP (1) EP2396005A1 (es)
JP (3) JP5896276B2 (es)
KR (2) KR20110118668A (es)
CN (2) CN104138370A (es)
AP (1) AP2011005795A0 (es)
AR (1) AR075424A1 (es)
AU (1) AU2010212865A1 (es)
BR (1) BRPI1013640A2 (es)
CA (1) CA2751833C (es)
CL (1) CL2011001757A1 (es)
CO (1) CO6410306A2 (es)
EA (1) EA021796B1 (es)
EC (1) ECSP11011275A (es)
GE (1) GEP20146120B (es)
HK (1) HK1203814A1 (es)
IL (1) IL213723A0 (es)
MA (1) MA33043B1 (es)
MX (1) MX344264B (es)
MY (1) MY161472A (es)
NZ (1) NZ594485A (es)
PE (1) PE20120002A1 (es)
PH (1) PH12016501607A1 (es)
SG (2) SG173587A1 (es)
TN (1) TN2011000413A1 (es)
TW (1) TWI478935B (es)
UA (1) UA106365C2 (es)
WO (1) WO2010092123A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2557801C (en) * 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
EP1926720B1 (en) * 2005-09-08 2010-12-15 Boehringer Ingelheim International GmbH CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
WO2008020011A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2667550A1 (en) * 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
JP5498392B2 (ja) 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US8603989B2 (en) * 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
JP6071198B2 (ja) 2008-07-15 2017-02-01 テラコス，インコーポレーテッド 重水素化ベンジルベンゼン誘導体及び使用方法
WO2010026214A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of cns disorders
US20110014284A1 (en) * 2009-02-13 2011-01-20 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
WO2010092125A1 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
PL2414363T3 (pl) 2009-03-31 2014-06-30 Boehringer Ingelheim Int Pochodne 1-heterocyklilo-1,5-dihydro-pirazolo[3,4-d]pirymidyn-4-onu i ich zastosowanie jako modulatorów PDE9A
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
PL2483286T3 (pl) * 2009-09-30 2017-04-28 Boehringer Ingelheim International Gmbh Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA110347C2 (uk) 2010-08-12 2015-12-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
JP5835598B2 (ja) * 2011-06-03 2015-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 神経弛緩剤で治療されている患者において代謝性障害を治療するためのｓｇｌｔ−２阻害剤
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102627535A (zh) * 2012-03-31 2012-08-08 天津药物研究院 含1,1-二苯基环丙基结构的化合物的制备方法
PL2981269T3 (pl) * 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA3175715A1 (en) 2013-04-18 2014-10-23 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE053906T2 (hu) * 2013-12-17 2021-07-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-inhibitorok macskafélék közé tartozó állatok anyagcsere-rendellenességeinek kezelésére
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
US10603300B2 (en) * 2014-01-23 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
PT3125882T (pt) 2014-04-01 2020-08-17 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
KR101973469B1 (ko) * 2014-09-02 2019-04-29 엘지전자 주식회사 방송 수신 장치, 방송 수신 장치의 동작 방법, 방송 수신 장치와 연동하는 연동 장치 및 연동 장치의 동작 방법
KR102539788B1 (ko) 2014-09-25 2023-06-07 베링거잉겔하임베트메디카게엠베하 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
US20180104268A1 (en) * 2015-04-30 2018-04-19 Boehringer Ingelheim International Gmbh Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
CN107847560A (zh) * 2015-06-22 2018-03-27 博格有限责任公司 包括eno1的组合物以及其在治疗肥胖症或超重和减少体重增加的方法中的用途
CN107995862B8 (zh) 2015-08-27 2021-12-03 勃林格殷格翰维特梅迪卡有限公司 包含sglt-2抑制剂之液态药物组合物
EP3362055B1 (en) 2015-10-15 2023-01-18 Boehringer Ingelheim International GmbH Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
WO2019087239A1 (ja) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート 腎症治療剤
AU2019254371A1 (en) * 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
CN110141555A (zh) * 2019-06-21 2019-08-20 江苏豪森药业集团有限公司 一种恩格列净片及其制备方法
EP4106744A1 (en) * 2020-02-17 2022-12-28 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
WO2022015743A1 (en) * 2020-07-14 2022-01-20 GyanRx Sciences, Inc. Methods of treating kidney stones
KR20230112426A (ko) * 2022-01-20 2023-07-27 주식회사 대웅제약 이나보글리플로진을 포함하는 개과 동물의 비만 예방 또는 치료용 약학 조성물
KR20240045138A (ko) * 2022-09-29 2024-04-05 주식회사 대웅제약 이나보글리플로진을 포함하는 심혈관 노화 질환 예방 또는 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
ES2258141T3 (es) * 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
CA2557801C (en) * 2004-03-16 2013-06-25 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7687469B2 (en) * 2004-12-16 2010-03-30 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
ATE445608T1 (de) * 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
ATE453656T1 (de) * 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JP5128474B2 (ja) * 2005-07-27 2013-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
DE602006017566D1 (de) 2005-08-30 2010-11-25 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
EP1926720B1 (en) 2005-09-08 2010-12-15 Boehringer Ingelheim International GmbH CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR059489A1 (es) * 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
AU2007252432B2 (en) * 2006-05-19 2011-11-17 Taisho Pharmaceutical Co., Ltd. C-phenyl glycitol compound
WO2008020011A1 (en) 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
CA2667550A1 (en) 2006-10-27 2008-05-02 Boehringer Ingelheim International Gmbh Crystalline form of 4-(.beta.-d-glucopyranos-1-yl)-1-methyl-2-[4-((s)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
WO2008055870A1 (en) * 2006-11-06 2008-05-15 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
BRPI0718596B8 (pt) 2006-11-09 2021-05-25 Boehringer Ingelheim Int composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
WO2010092125A1 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
US20140303097A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof

Also Published As

Publication number Publication date
EA201101189A1 (ru) 2012-03-30
CN102316875A (zh) 2012-01-11
IL213723A0 (en) 2011-07-31
US20170020907A1 (en) 2017-01-26
TN2011000413A1 (en) 2013-03-27
US20120196812A1 (en) 2012-08-02
TWI478935B (zh) 2015-04-01
MY161472A (en) 2017-04-14
WO2010092123A8 (en) 2011-06-30
SG173587A1 (en) 2011-09-29
HK1203814A1 (en) 2015-11-06
CO6410306A2 (es) 2012-03-30
AR075424A1 (es) 2011-03-30
AP2011005795A0 (en) 2011-08-31
US20110046087A1 (en) 2011-02-24
EP2396005A1 (en) 2011-12-21
CA2751833C (en) 2018-11-06
AU2010212865A8 (en) 2011-11-17
MA33043B1 (fr) 2012-02-01
US20160158264A1 (en) 2016-06-09
WO2010092123A1 (en) 2010-08-19
US20200069713A1 (en) 2020-03-05
ECSP11011275A (es) 2011-09-30
US20220313716A1 (en) 2022-10-06
NZ594485A (en) 2013-07-26
KR20170028452A (ko) 2017-03-13
BRPI1013640A2 (pt) 2019-09-24
PH12016501607A1 (en) 2017-10-18
JP2017052787A (ja) 2017-03-16
MX2011008214A (es) 2011-11-29
SG10201600204YA (en) 2016-02-26
CN104138370A (zh) 2014-11-12
US20210283156A1 (en) 2021-09-16
AU2010212865A1 (en) 2011-07-21
UA106365C2 (ru) 2014-08-26
MX344264B (es) 2016-12-09
JP2012517975A (ja) 2012-08-09
KR20110118668A (ko) 2011-10-31
US20140031301A1 (en) 2014-01-30
TW201040194A (en) 2010-11-16
JP2015042691A (ja) 2015-03-05
EA021796B1 (ru) 2015-09-30
PE20120002A1 (es) 2012-02-12
GEP20146120B (en) 2014-07-25
CA2751833A1 (en) 2010-08-19
JP5896276B2 (ja) 2016-03-30

Similar Documents

Publication Publication Date Title
CL2011001757A1 (es) Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico.
CL2012000793A1 (es) Composicion farmaceutica que comprende 1-cloro-4-(3-d-glucopiranos-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]benceno, clorhidrato de metformina y uno o mas excipientes farmaceuticos.
CL2011002041A1 (es) Compuestos derivaados de 4-isopropilfenilglucitol, inhibidores de sglt1; preparacion farmaceutica; y su uso como agente para mejorar la hiperglucemia posprandial y como agente profilactico o terapeutico para la diabetes.
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CL2013001436A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CL2007001439A1 (es) Metodo continuo para producir extracto de mosto mediante remojado de la malta por de coccion que comprende emplear uno o mas complementos que contienen almidon como una fuente de azucares fermentables.
CL2011001254A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente a cd38 y al menos melfalan; y su uso para el tratamiento contra el cancer.
CL2013003455A1 (es) Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion.
CL2013001471A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
CL2009000707A1 (es) Composicion controladora de enfermedades de plantas que comprende un compuesto derivado de pirazolinona y al menos otros fungicidas derivados de estrobirulina como dimoxiestrobina; y metodo para controlar una enfermedad en planta mediante el uso de la composicion.
CL2011000501A1 (es) Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras.
CL2011002648A1 (es) Composicion topica que comprende un compuesto derivado de 1,2,4-tiadiazol o tiourea, un agente modificador de la viscosidad, un conservante y agua; estuche para la composicion; metodo para preparar la composicion; y uso para tratar una enfermedad o trastorno dermatologico mediado por un receptor de melanocortina tal como acne.
CL2011001735A1 (es) Composicion farmaceutica que comprende: a) el inhibidor de sglt2 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)-bencil]-benceno, b) el inhibidor de dppiv linagliptina y c) un tercer agente antidiabetico que es clorhidrato de metformina; y su uso para tratar la diabetes mellitus tipo 2.
NI201001033A (es) Formas cristalinas de dimetoxi docetaxel y metodo para preparar el mismo.
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
AR053720A1 (es) Forma cristalina de 1-cloro-4-((beta)-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, un metodo para su preparacion y el uso del mismo para preparar medicamentos
BRPI0913587A2 (pt) Composição, agente pesticida, método para controlar fundos prejudiciais fitopatogênicos, semente, uso de um composto e de um outro composto, e, composição.
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
BRPI0803374A2 (pt) compostos polihidróxi como agentes de extinção de polimerização
PE20100260A1 (es) Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol
TN2009000521A1 (en) Rnai inhibition of alpha-enac expression
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
CL2008000403A1 (es) Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos.